| Style | Citing Format |
|---|---|
| MLA | Akhondzadeh S, Ghajar A. "Author's Reply to the Letter to the Editor by Fountoulakis." Pharmacopsychiatry, vol. 51, no. 3, 2018, pp. 106-107. |
| APA | Akhondzadeh S, Ghajar A (2018). Author's Reply to the Letter to the Editor by Fountoulakis. Pharmacopsychiatry, 51(3), 106-107. |
| Chicago | Akhondzadeh S, Ghajar A. "Author's Reply to the Letter to the Editor by Fountoulakis." Pharmacopsychiatry 51, no. 3 (2018): 106-107. |
| Harvard | Akhondzadeh S, Ghajar A (2018) 'Author's Reply to the Letter to the Editor by Fountoulakis', Pharmacopsychiatry, 51(3), pp. 106-107. |
| Vancouver | Akhondzadeh S, Ghajar A. Author's Reply to the Letter to the Editor by Fountoulakis. Pharmacopsychiatry. 2018;51(3):106-107. |
| BibTex | @article{ author = {Akhondzadeh S and Ghajar A}, title = {Author's Reply to the Letter to the Editor by Fountoulakis}, journal = {Pharmacopsychiatry}, volume = {51}, number = {3}, pages = {106-107}, year = {2018} } |
| RIS | TY - JOUR AU - Akhondzadeh S AU - Ghajar A TI - Author's Reply to the Letter to the Editor by Fountoulakis JO - Pharmacopsychiatry VL - 51 IS - 3 SP - 106 EP - 107 PY - 2018 ER - |